Efficacy and Safety of Basiliximab in Hepatitis C Virus Positive Patients Undergoing Liver Transplantation
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The natural history of HCV infection in liver transplant recipients may be accelerated when
compared to that in patients with normal immune systems.
The objective of this trial is to assess the efficacy and safety of basiliximab, in
combination with cyclosporin and MMF on the success rate of liver transplants for HCV related
cirrhosis, in comparison with standard steroid treatment.